Three-Drug shield tested to protect cancer patients after transplant
NCT ID NCT07249346
Summary
This study is testing a combination of three medications given after a stem cell transplant to prevent a dangerous complication called graft-versus-host disease (GVHD). It will enroll 124 adults with leukemia or similar blood cancers who are receiving a transplant from a donor. The main goal is to see if this new drug regimen helps patients survive without developing the most severe forms of GVHD in the first six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.